SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

Sponsor
Li Zhang
Study ID
NCT05583409
Status
Unknown

Conditions

  • Stage IV Non-small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving treatment with Osimertinib

Key Dates

Start date
Jan 1, 2023
Status verified
Oct 2022
Primary completion
Dec 30, 2024
Completion
Dec 30, 2025

Study Design

Enrollment
72 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Osimertinib plus SBRT
    SBRT with photon and dose is 40Gy/5F after three months after Osimertinib treatment
  • Active Comparator: Osimertinib
    Osimertinib 80mg, po, Qd

Primary Outcome Measure

PFS [ Time Frame: 2 years ]

Central Contacts

Related Studies